Skip to main content
SpringerLink
Log in

Infection and Cancer Screening in Living Donor Candidates

  • Chapter
  • First Online:
Living Kidney Donation

Abstract

Living kidney donation has the potential to greatly improve the health and longevity of patients with kidney disease. However, it is crucial to carefully evaluate living donor candidates to minimize the risk of inadvertent harm to the recipient by transmission of infectious diseases or malignancy, as well as to support the donor’s own health and well-being. In this chapter we outline the essential infectious disease screening for living donor candidates, with attention to geographic considerations and optimal screening modalities. We also discuss the assessment of malignancy in living donor candidates with specific discussion of transmission risks from donors with a cancer history.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Organ Procurement and Transplantation Network (OPTN). Recognizing seasonal and geographically endemic infections in organ donors: considerations during living donor evaluation. Available at: https://optn.transplant.hrsa.gov/media/1138/seasonal_disease_guidance.pdf. Accessed: 7 Sept 2020.

  2. Lentine KL, Kasiske BL, Levey AS, Adams PL, Alberú J, Bakr MA, et al. KDIGO clinical practice guideline on the evaluation and care of living kidney donors. Transplantation. 2017;101.(8S Suppl 1:S1–S109. https://doi.org/10.1097/tp.0000000000001769.

  3. Seem DL, Lee I, Umscheid CA, Kuehnert MJ, United States Public Health Service. PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation. Public Health Rep. 2013;128(4):247–343. https://doi.org/10.1177/003335491312800403.

  4. Natov SN, Pereira BJ. Transmission of viral hepatitis by kidney transplantation: donor evaluation and transplant policies (part 1: hepatitis B virus). Transpl Infect Dis. 2002;4(3):117–23. https://doi.org/10.1034/j.1399-3062.2002.t01-1-01002.x.

  5. Natov SN. Transmission of viral hepatitis by kidney transplantation: donor evaluation and transplant policies (part 2: hepatitis C virus). Transpl Infect Dis. 2002;4(3):124–31. https://doi.org/10.1034/j.1399-3062.2002.t01-2-01002.x.

  6. Blumberg EA, Ison MG, Pruett TL, Segev DL, Optimal Testing of the Live Organ Donor Consensus Conference Participants. Optimal testing of the live organ donor for blood-borne viral pathogens: the report of a consensus conference. Am J Transplant. 2013;13(6):1405–15. Epub 2013 Apr 19. https://doi.org/10.1111/ajt.12205.

  7. Ison MG, Grossi P, AST Infectious Diseases Community of Practice. Donor-derived infections in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):22–30. https://doi.org/10.1111/ajt.12095.

  8. Singh N, Huprikar S, Burdette SD, Morris MI, Blair JE, Wheat LJ, American Society of Transplantation, Infectious diseases Community of Practice, Donor-Derived Fungal Infection Working Group. Donor-derived fungal infections in organ transplant recipients: guidelines of the American Society of Transplantation, infectious diseases community of practice. Am J Transplant. 2012;12(9):2414–28. https://doi.org/10.1111/j.1600-6143.2012.04100.x.

  9. Clemente WT, Pierrotti LC, Abdala E, Morris MI, Azevedo LS, López-Vélez R, Cuenca-Estrella M, et al. Recommendations for management of endemic diseases and travel medicine in solid-organ transplant recipients and donors: Latin America. Transplantation. 2018;102(2):193–208. https://doi.org/10.1097/tp.0000000000002027.

  10. Levi ME, Kumar D, Green M, Ison MG, Kaul D, Michaels MG, et al. Considerations for screening live kidney donors for endemic infections: a viewpoint on the UNOS policy. Am J Transplant. 2014;14(5):1003–11. https://doi.org/10.1111/ajt.12666.

  11. Chin-Hong PV, Schwartz BS, Bern C, Montgomery SP, Kontak S, Kubak B, et al. Screening and treatment of Chagas disease in organ transplant recipients in the United States: recommendations from the Chagas in transplant working group. Am J Transplant. 2011;11(4):672–80. https://doi.org/10.1111/j.1600-6143.2011.03444.x.

  12. Razonable RR, Humar A, AST Infectious diseases Community of Practice. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):93–106. https://doi.org/10.1111/ajt.12103.

  13. Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm. 2005;62(Suppl 1):S7–S13. https://doi.org/10.1093/ajhp/62.suppl_1.s7.

  14. Kotton C, Kumar D, Caliendo AM, Åsberg A, Chou S, Danziger-Isakov L, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transp J. 2013;96(4):333–60. https://doi.org/10.1097/tp.0b013e31829df29d.

  15. Abbott KC, Hypolite IO, Viola R, Poropatich RK, Hshieh P, Cruess D, et al. Hospitalizations for cytomegalovirus disease after renal transplantation in the United States. Epidemiology. 2002;12(6):402–9. https://doi.org/10.1016/s1047-2797(01)00283-6.

  16. Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant. 2006;6(9):2134–43. https://doi.org/10.1111/j.1600-6143.2006.01413.x.

  17. Hartmann A, Sagedal S, Hjelmesaeth J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation. 2006;82(2 Suppl):S15–7. https://doi.org/10.1097/01.tp.0000230460.42558.b0.

  18. Walker RC, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis. 1995;20(5):1346–53. https://doi.org/10.1093/clinids/20.5.1346.

  19. McDonald RA, Smith JM, Ho M, Lindblad R, Ikle D, Grimm P, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant. 2008;8(5):984–9. https://doi.org/10.1111/j.1600-6143.2008.02167.x.

  20. Centers for Disease Control and Prevention. Sexually transmitted diseases surveillance 2017: syphilis. Available at: https://www.cdc.gov/std/stats17/syphilis.htm. Accessed: 7 Sept 2020.

  21. Cortes NJ, Afzali B, MacLean D, Goldsmith DJ, O’Sullivan H, Bingham J, et al. Transmission of syphilis by solid organ transplantation. Am J Transplant. 2006;6(10):2497–9. Epub 2006 Jul 6. https://doi.org/10.1111/j.1600-6143.2006.01461.x.

  22. Tariciotti L, Das I, Dori L, Perera MT, Bramhall SR. Asymptomatic transmission of Treponema pallidum (syphilis) through deceased donor liver transplantation. Transpl Infect Dis. 2012;14:321–5. https://doi.org/10.1111/j.1399-3062.2012.00745.x.

  23. Theodoropoulos N, Jaramillo A, Penugonda S, Wasik C, Brooks K, Ladner DP, et al. Improving syphilis screening in deceased organ donors. Transplantation. 2015;99(2):438–43. https://doi.org/10.1097/tp.0000000000000323.

  24. Seña AC, White BL, Sparling PF. Novel Treponema pallidum serologic tests: a paradigm shift in syphilis screening for the 21st century. Clin Infect Dis. 2010;51(6):700–8. https://doi.org/10.1086/655832.

  25. Ison MG, Llata E, Conover CS, Friedewald JJ, Gerber SI, Grigoryan A, et al. Transmission of human immunodeficiency virus and hepatitis C virus from an organ donor to four transplant recipients. Am J Transplant. 2011;11(6):1218–25. https://doi.org/10.1111/j.1600-6143.2011.03597.x.

  26. Centers for Disease Control and Prevention (CDC). HIV transmitted from a living organ donor--New York City, 2009. MMWR Morb Mortal Wkly Rep. 2011;60(10):297–301. https://pubmed.ncbi.nlm.nih.gov/21412210/.

  27. Echenique IA, Cohen D, Rudow DL, Ison MG. Impact of repeat testing of living kidney donors within 14 days of the transplant procedure: a multicenter retrospective survey. Transpl Infect Dis. 2014;16(3):403–11. https://doi.org/10.1111/tid.12219.

  28. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion. 2005;45(2):254–64. https://doi.org/10.1111/j.1537-2995.2004.04215.x.

  29. Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS). Organ procurement and transplantation: Implementation of the HIV Organ Policy Equity Act. Final rule. Fed Regist. 2015;80(89):26464–7. https://pubmed.ncbi.nlm.nih.gov/25985481/.

  30. Bernstein L. First living HIV-positive donor provides kidney for transplant in medical breakthrough. The Washington Post 2019. Available at: https://www.washingtonpost.com/national/health-science/first-living-hiv-positive-donor-provides-kidney-for-transplant-in-medical-breakthrough/2019/03/28/29894312-50bc-11e9-88a1-ed346f0ec94f_story.html. Accessed: 7 Sept 2020.

  31. de Vera ME, Volk ML, Ncube Z, Blais S, Robinson M, Allen N, et al. Transplantation of hepatitis C virus (HCV) antibody positive, nucleic acid test negative donor kidneys to HCV negative patients frequently results in seroconversion but not HCV viremia. Am J Transplant. 2018;18(10):2451–6. https://doi.org/10.1111/ajt.15031.

  32. Reese PP, Abt PL, Blumberg EA, Van Deerlin VM, Bloom RD, Potluri VS, et al. Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial. Ann Intern Med. 2018;169(5):273–81. https://doi.org/10.7326/m18-0749.

  33. Goldberg DS, Abt PL, Reese PP, THINKER Trial Investigators. Transplanting HCV-infected kidneys into uninfected recipients. N Engl J Med. 2017;377(11):1105. https://doi.org/10.1056/nejmc1709315.

  34. Huprikar S, Danziger-Isakov L, Ahn J, Naugler S, Blumberg E, Avery RK, et al. Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. Am J Transplant. 2015;15(5):1162–72. https://doi.org/10.1111/ajt.13187.

  35. Manos NE, Ferebee SH, Kerschbaum WF. Geographic variation in the prevalence of histoplasmin sensitivity. Dis Chest. 1956;29(6):649–68. https://doi.org/10.1378/chest.29.6.649.

  36. Sunenshine RH, Anderson S, Erhart L, Vossbrink A, Kelly PC, Engelthaler D, et al. Public health surveillance for coccidioidomycosis in Arizona. Ann N Y Acad Sci. 2007;1111:96–102. https://doi.org/10.1196/annals.1406.045.

  37. Blair JE, Logan JL. Coccidioidomycosis in solid organ transplantation. Clin Infect Dis. 2001;33(9):1536–44. https://doi.org/10.1086/323463.

  38. Kusne S, Taranto S, Covington S, Kaul DR, Blumberg EA, Wolfe C, et al. Coccidioidomycosis transmission through organ transplantation: a report of the OPTN Ad Hoc Disease Transmission Advisory Committee. Am J Transplant. 2016;16(12):3562–7. https://doi.org/10.1111/ajt.13950.

  39. Centers for Disease Control and Prevention (CDC). Transmission of Strongyloides stercoralis through transplantation of solid organs--Pennsylvania, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(14):264–6. https://pubmed.ncbi.nlm.nih.gov/23575239/.

  40. Le M, Ravin K, Hasan A, Clauss H, Muchant DG, Pasko JK, et al. Single donor-derived strongyloidiasis in three solid organ transplant recipients: case series and review of the literature. Am J Transplant. 2014;14(5):1199–206. https://doi.org/10.1111/ajt.12670.

  41. Abanyie FA, Gray EB, Delli Carpini KW, Yanofsky A, McAuliffe I, Rana M, et al. Donor-derived Strongyloides stercoralis infection in solid organ transplant recipients in the United States, 2009–2013. Am J Transplant. 2015;15(5):1369–75. https://doi.org/10.1111/ajt.13137.

  42. Coster LO. Parasitic infections in solid organ transplant recipients. Infect Dis Clin North Am. 2013;27(2):395–427. Epub 2013 Mar 29. https://doi.org/10.1016/j.idc.2013.02.008.

  43. Abdalhamid BA, Al Abadi AN, Al Saghier MI, Joudeh AA, Shorman MA, Amr SS. Strongyloides stercoralis infection in kidney transplant recipients. Saudi J Kidney Dis Transpl. 2015;26(1):98–102. https://doi.org/10.4103/1319-2442.148752.

  44. World Health Organization. Chagas disease. Available at: http://www.who.int/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis). Accessed: 7 Sept 2020.

  45. Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis. 2009;49(5):e52–4. https://doi.org/10.1086/605091.

  46. Huprikar S, Bosserman E, Patel G, Moore A, Pinney S, Anyanwu A, et al. Donor-derived Trypanosoma cruzi infection in solid organ recipients in the United States, 2001–2011. Am J Transplant. 2013;13(9):2418–25. https://doi.org/10.1111/ajt.12340.

  47. Pierrotti LC, Carvalho NB, Amorin JP, Pascual J, Kotton CN, Lopez-Velez R. Chagas disease recommendations for solid-organ transplant recipients and donors. Transplantation. 2018;102(2S Suppl2):S1–7. https://doi.org/10.1097/tp.0000000000002019.

  48. Ison MG, Nalesnik MA. An update on donor-derived disease transmission in organ transplantation. Am J Transplant. 2011;11(6):1123–30. https://doi.org/10.1111/j.1600-6143.2011.03493.x.

  49. Morris MI, Daly JS, Blumberg E, Kumar D, Sester M, Schluger N, et al. Diagnosis and management of tuberculosis in transplant donors: a donor-derived infections consensus conference report. Am J Transplant. 2012;12(9):2288–300. https://doi.org/10.1111/j.1600-6143.2012.04205.x.

  50. Winston DJ, Vikram HR, Rabe IB, Dhillon G, Mulligan D, Hong JC, et al. Donor-derived West Nile virus infection in solid organ transplant recipients: report of four additional cases and review of clinical, diagnostic, and therapeutic features. Transplantation. 2014;97(9):881–9. https://doi.org/10.1097/tp.0000000000000024.

  51. Iwamoto M, Jernigan DB, Guasch A, Trepka MJ, Blackmore CG, Hellinger WC, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med. 2003;348(22):2196–203. https://doi.org/10.1056/nejmoa022987.

  52. Centers for Disease Control and Prevention. West Nile virus. Available at: https://www.cdc.gov/westnile/index.html. Accessed: 7 Sept 2020.

  53. Burakoff A, Lehman J, Fischer M, Staples JE, Lindsey NP. West Nile virus and other nationally notifiable arboviral diseases - United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(1):13–7. https://doi.org/10.15585/mmwr.mm6701a3.

  54. Kumar D, Prasas GV, Zaltzman J, Levy GA, Humar A. Community-acquired West Nile virus infection in solid-organ transplant recipients. Transplantation. 2004;77:339–402. https://doi.org/10.1097/01.tp.0000101435.91619.31.

  55. Organ Procurement and Transplantation Network (OPTN). Identifying risk factors for West Nile virus (WNV) during evaluation of potential living donors. Available at: https://optn.transplant.hrsa.gov/resources/guidance/identifying-risk-factors-for-west-nile-virus-wnv-during-evaluation-of-potential-living-donors/. Accessed: 7 Sept 2020.

  56. Busch MP, Kleinman SH, Tobler LH, Kamel HT, Norris PJ, Walsh I, et al. Virus and antibody dynamics in acute West Nile virus infection. J Infect Dis. 2008;198(7):984–93. https://doi.org/10.1086/591467.

  57. Centers for Disease Control and Prevention. Zika virus. https://www.cdc.gov/zika/index.html. Accessed: 7 Sept 2020.

  58. Organ Procurement and Transplantation Network (OPTN). Guidance on Zika virus. Available at: https://optn.transplant.hrsa.gov/news/guidance-on-zika-virus/. Accessed: 7 Sept 2020.

  59. Reynolds MR, Jones AM, Petersen EE, Lee EH, Rice ME, Bingham A, et al. Vital signs: update on Zika virus-associated birth defects and evaluation of all U.S. infants with congenital Zika virus exposure - U.S. Zika pregnancy registry, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(13):366–73. https://doi.org/10.15585/mmwr.mm6613e1.

  60. Satterfield-Nash A, Kotzky K, Allen J, Bertolli J, Moore CA, Pereira IO, et al. Health and development at age 19–24 months of 19 children who were born with microcephaly and laboratory evidence of congenital Zika virus infection during the 2015 Zika virus outbreak - Brazil, 2017. MMWR Morb Mortal Wkly Rep. 2017;66(49):1347–51. https://doi.org/10.15585/mmwr.mm6649a2.

  61. Polen KD, Gilboa SM, Hills S, Oduyebo T, Kohl KS, Brooks JT, et al. Update: interim guidance for preconception counseling and prevention of sexual transmission of Zika virus for men with possible Zika virus exposure - United States, august 2018. MMWR Morb Mortal Wkly Rep. 2018;67(31):868–71. https://doi.org/10.15585/mmwr.mm6731e2.

  62. Magnus MM, Espósito DLA, Costa VAD, Melo PS, Costa-Lima C, Fonseca BALD. Risk of Zika virus transmission by blood donations in Brazil. Hematol Transfus Cell Ther. 2018;40(3):250–4. https://doi.org/10.1016/j.htct.2018.01.011.

  63. Tong A, Chapman JR, Wong G, de Bruijn J, Craig JC. Screening and follow-up of living kidney donors: a systematic review of clinical practice guidelines. Transplantation. 2011;92(9):962–72. https://doi.org/10.1097/tp.0b013e3182328276.

  64. British Transplant Society (BTS). Guidelines for living donor kidney transplantation. 4th ed. 2018. Available at: https://bts.org.uk/wp-content/uploads/2018/07/FINAL_LDKT-guidelines_June-2018.pdf. Accessed: 7 Sept 2020.

  65. American Cancer Society (ACS). Guidelines for the early detection of cancer. 2018. Available at: https://www.cancer.org/healthy/find-cancer-early/cancer-screening-guidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer.html. Accessed: 7 Sept 2020.

  66. Australian Government Department of Health. Cancer screening. 2018. Available at: http://www.cancerscreening.gov.au/. Accessed: 7 Sept 2020.

  67. Xiao D, Craig JC, Chapman JR, Dominguez-Gil B, Tong A, Wong G. Donor cancer transmission in kidney transplantation: a systematic review. Am J Transplant. 2013;13(10):2645–52. https://doi.org/10.1111/ajt.12430.

  68. Desai R, Collett D, Watson CJ, Johnson P, Evans T, Neuberger J. Cancer transmission from organ donors-unavoidable but low risk. Transplantation. 2012;94(12):1200–7. https://doi.org/10.1097/tp.0b013e318272df41.

  69. Eccher A, Lombardini L, Girolami I, Puoti F, Zaza G, Gambaro G, et al. How safe are organs from deceased donors with neoplasia? The results of the Italian Transplantation Network. J Nephrol. 2019;32(2):323–30. https://doi.org/10.1007/s40620-018-00573-z.

  70. Kauffman HM, Cherikh WS, McBride MA, Cheng Y, Hanto DW. Deceased donors with a past history of malignancy: an organ procurement and transplantation network/united network for organ sharing update. Transplantation. 2007;84(2):272–4. https://doi.org/10.1097/01.tp.0000267919.93425.fb.

  71. Kauffman HM, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies. Transplantation. 2002;74(3):358–62. https://doi.org/10.1097/00007890-200208150-00011.

  72. Nalesnik MA, Woodle ES, Dimaio JM, Vasudev B, Teperman LW, Covington S, et al. Donor-transmitted malignancies in organ transplantation: assessment of clinical risk. Am J Transplant. 2011;11(6):1140–7. https://doi.org/10.1111/j.1600-6143.2011.03565.x.

  73. Desai R, Collett D, Watson CJE, Johnson P, Evans T, Neuberger J. Estimated risk of cancer transmission from organ donor to graft recipient in a national transplantation registry. Br J Surg. 2014;101(7):768–74. https://doi.org/10.1002/bjs.9460.

  74. Buell JF, Beebe TM, Trofe J, Gross TG, Alloway RR, Hanaway MJ, et al. Donor transmitted malignancies. Ann Transplant. 2004;9(1):53–6. https://pubmed.ncbi.nlm.nih.gov/15478892/.

  75. Watson CJE, Roberts R, Wright KA, Greenberg DC, Rous BA, Brown CH, et al. How safe is it to transplant organs from deceased donors with primary intracranial malignancy? An analysis of UK registry data. Am J Transplant. 2010;10(6):1437–44. https://doi.org/10.1111/j.1600-6143.2010.03130.x.

  76. Engels EA, Castenson D, Pfeiffer RM, Kahn A, Pawlish K, Goodman MT, et al. Cancers among US organ donors: a comparison of transplant and cancer registry diagnoses. Am J Transplant. 2014;14(6):1376–82. https://doi.org/10.1111/ajt.12683.

  77. Organ Procurement and Transplantation Network (OPTN) / United Network for Organ Sharing (UNOS). Policy 15: identification of transmissible diseases. Available at: https://optn.transplant.hrsa.gov/governance/policies/. Accessed: 7 Sept 2020.

  78. Chapman J, D’Errico-Grigioni A, Matsanz R. The transmission of malignancies. NOTIFY: exploring vigilance notification for organs, tissues and cells. Bologna: Testi Centro Nazionale Trapianti; 2011. p. 78–97.

    Google Scholar 

  79. European Directorate for the Quality of Medicines & Healthcare. Guide to the quality and safety of organs for transplantation. 2018. Available at: https://www.edqm.eu/en/guide-quality-and-safety-organs-transplantation. Accessed: 7 Sept 2020.

  80. Lugo-Baruqui JA, Guerra G, Chen L, Burke GW, Gaite JA, Ciancio G. Living donor renal transplantation with incidental renal cell carcinoma from donor allograft. Transpl Int. 2015;28(9):1126–30. https://doi.org/10.1111/tri.12594.

  81. Lugo-Baruqui A, Guerra G, Arocha A, Burke GW, Ciancio G. Use of kidneys with small renal tumors for transplantation. Curr Urol Rep. 2016;17(1):3. https://doi.org/10.1007/s11934-015-0557-z.

  82. Sener A, Uberoi V, Bartlett ST, Kramer AC, Phelan MW. Living-donor renal transplantation of grafts with incidental renal masses after ex-vivo partial nephrectomy. BJU Int. 2009;104(11):1655–60. https://doi.org/10.1111/j.1464-410x.2009.08681.x.

  83. Nicol DL, Preston JM, Wall DR, Griffin AD, Campbell SB, Isbel NM, et al. Kidneys from patients with small renal tumours: a novel source of kidneys for transplantation. BJU Int. 2008;102(2):188–92. https://doi.org/10.1111/j.1464-410x.2008.07562.x.

Download references

Author information

Authors and Affiliations

  1. Renal, Electrolyte and Hypertension Division, Department of Medicine, Perelman School of Medicine, Philadelphia, PA, USA

    Mary Ann Lim & Deirdre Sawinski

  2. Sydney School of Public Health, University of Sydney, Sydney, NSW, Australia

    Eric Au & Germaine Wong

  3. Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, Philadelphia, PA, USA

    Blair Weikert

Authors
  1. Mary Ann Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric Au
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Blair Weikert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Germaine Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Deirdre Sawinski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deirdre Sawinski .

Editor information

Editors and Affiliations

  1. Center for Abdominal Transplantation, Division of Nephrology, Saint Louis University School of Medicine, St. Louis, MO, USA

    Krista L. Lentine

  2. Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

    Beatrice P. Concepcion

  3. Section of Nephrology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA

    Edgar V. Lerma

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lim, M.A., Au, E., Weikert, B., Wong, G., Sawinski, D. (2021). Infection and Cancer Screening in Living Donor Candidates. In: Lentine, K.L., Concepcion, B.P., Lerma, E.V. (eds) Living Kidney Donation. Springer, Cham. https://doi.org/10.1007/978-3-030-53618-3_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-53618-3_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-53617-6

  • Online ISBN: 978-3-030-53618-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation